Treatment of outpatient urinary tract infections with cinoxacin.
This paper describes an open assessment of cinoxacin in the treatment of 30 outpatients with symptomatic urinary tract infections caused by Escherichia coli, Klebsiella, Proteus mirabilis, and Enterobacter. Twenty-seven patients (90 percent) had a satisfactory clinical response and in 26 patients, there was a satisfactory microbiological response with elimination of the pathogen. Mild side effects were reported by three patients, none of whom stopped therapy. It is concluded that cinoxacin will be useful in the treatment of urinary tract disease because of the high urinary antibacterial activity produced. The relatively low incidence of side effects and convenience of twice-daily dosage should encourage good compliance by patients treated outside the hospital setting.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002937:Cinoxacin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D011724:Pyridazines / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D011724:Pyridazines; D002937:Cinoxacin